Jacobs & Co. CA Purchases 571 Shares of Johnson & Johnson (NYSE:JNJ)


Share on StockTwits

Jacobs & Co. CA lifted its position in Johnson & Johnson (NYSE:JNJ) by 1.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 60,166 shares of the company’s stock after buying an additional 571 shares during the period. Jacobs & Co. CA’s holdings in Johnson & Johnson were worth $9,888,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Bank of New York Mellon Corp raised its holdings in shares of Johnson & Johnson by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 31,958,260 shares of the company’s stock valued at $5,029,590,000 after purchasing an additional 1,628,229 shares during the last quarter. Norges Bank purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $4,370,566,000. Morgan Stanley raised its holdings in shares of Johnson & Johnson by 7.3% during the fourth quarter. Morgan Stanley now owns 24,111,028 shares of the company’s stock valued at $3,794,594,000 after purchasing an additional 1,638,263 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Johnson & Johnson by 4.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 17,236,904 shares of the company’s stock valued at $2,712,680,000 after purchasing an additional 692,267 shares during the last quarter. Finally, California Public Employees Retirement System raised its holdings in shares of Johnson & Johnson by 9.7% during the fourth quarter. California Public Employees Retirement System now owns 11,649,355 shares of the company’s stock valued at $1,833,375,000 after purchasing an additional 1,032,575 shares during the last quarter. Hedge funds and other institutional investors own 67.25% of the company’s stock.

Shares of NYSE:JNJ traded up $0.13 during midday trading on Thursday, reaching $163.74. 64,577 shares of the company were exchanged, compared to its average volume of 8,177,090. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51. The business’s fifty day moving average is $161.06 and its two-hundred day moving average is $154.38. Johnson & Johnson has a one year low of $133.65 and a one year high of $173.65. The stock has a market cap of $431.08 billion, a PE ratio of 25.76, a price-to-earnings-growth ratio of 3.06 and a beta of 0.70.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Monday, January 25th. The company reported $1.86 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.82 by $0.04. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The firm had revenue of $22.50 million during the quarter, compared to analyst estimates of $21.62 billion. During the same quarter in the prior year, the business earned $1.88 earnings per share. Johnson & Johnson’s revenue for the quarter was up 8.7% on a year-over-year basis. As a group, sell-side analysts expect that Johnson & Johnson will post 7.99 EPS for the current year.

Several research analysts have recently weighed in on JNJ shares. JPMorgan Chase & Co. boosted their price objective on shares of Johnson & Johnson from $157.00 to $175.00 and gave the company a “neutral” rating in a report on Wednesday, January 27th. Morgan Stanley upped their target price on shares of Johnson & Johnson from $178.00 to $187.00 and gave the company an “overweight” rating in a report on Wednesday, January 27th. Cantor Fitzgerald upped their target price on shares of Johnson & Johnson from $180.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, January 26th. Cowen upped their target price on shares of Johnson & Johnson from $170.00 to $195.00 and gave the company an “outperform” rating in a report on Wednesday, January 27th. Finally, Raymond James upped their target price on shares of Johnson & Johnson from $158.00 to $183.00 and gave the company an “outperform” rating in a report on Wednesday, January 27th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $178.60.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Story: Why do company’s buyback their stock?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.